Seidman Cancer Center

Wednesday, May 16, 2018

Case Western Reserve University, Lucid Diagnostics sign license agreement to commercialize fast, accurate Barrett’s Esophagus detector

CLEVELAND — Case Western Reserve University and Lucid Diagnostics, a subsidiary of publicly traded New York-based medical device company, PAVmed Inc. (Nasdaq: PAVM), have signed an exclusive license agreement to commercialize a technology that quickly and accurately detects Barrett’s Esophagus, the primary precursor of esophageal cancer.
 
The technology, called EsoCheck, combines a non-invasive, cell-sampling device with highly accurate DNA biomarkers to detect the condition.
 
The company is based on discoveries by three scientific founders: Sanford Markowitz, the  Markowitz-Ingalls Professor of Cancer Genetics and Distinguished University Professor at Case Western Reserve and medical oncologist at University Hospitals Seidman Cancer Center; Amitabh Chak, professor of medicine at Case Western Reserve School of Medicine, gastroenterologist at University Hospitals Digestive Health Institute and director of the Advanced Technology and Innovation Center of Excellence at University Hospitals Division of Gastroenterology; and Joseph Willis, professor of pathology and pathology vice chair for clinical affairs at University Hospitals Cleveland Medical Center. 




Friday, February 02, 2018

University Hospitals launches new vision statement: ‘Advancing the Science of Health and the Art of Compassion’

CLEVELAND – University Hospitals is launching a new vision statement to guide the future success and aspirations of the health system, its 18 hospitals, 26,000 employees and 1.3 million patients annually served.
 
The statement -- Advancing the Science of Health and the Art of Compassion -- defines UH as a nationally leading academic medical research center and health system grounded in pioneering research, new technologies and compassionate and personalized patient care.
 
As part of the vision launch, UH also will kick off an advertising campaign with two commercials airing during the Super Bowl on Feb. 4.  The commercials are part of a series of spots featuring real patients and their caregivers sharing their UH experiences. 
 
Following their initial showings, the commercials will be shown on TV stations in Northeast Ohio, in conjunction with ads on radio, in newspapers and digital platforms.


Thursday, February 01, 2018

University Hospitals recruits top scientist to lead research at UH Seidman Cancer Center

CLEVELAND – University Hospitals recently announced the recruitment of one of the nation’s leading scientists, Quintin Pan, PhD.
 
Dr.  Pan joins University Hospitals as Deputy Director for Research at UH Seidman Cancer Center and Professor of Medicine at Case Western Reserve University School of Medicine.
 
He will focus on translational cancer research ranging from novel target identification and drug discovery, to pre-clinical validation and human clinical trials. In particular, his laboratory has elucidated key insights regarding genetic determinants of cancer that provide the foundation for novel therapies to treat aggressive head and neck cancers. 


Wednesday, January 17, 2018

Researchers develop highly sensitive swallowable test to detect pre-cancerous Barrett's Esophagus

CLEVELAND — Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett’s esophagus that offers promise for preventing deaths from esophageal adenocarcinoma.
 
Barrett’s esophagus (BE) is the precursor lesion of esophageal adenocarcinoma (EAC), a highly lethal cancer with more than 80 percent mortality at five years. Lethal EAC can be prevented when patients are diagnosed at the precursor stage of Barrett’s esophagus, and early foci of near cancerous changes (dysplasias) are ablated. However, detection of BE has traditionally necessitated endoscopy, an expensive and invasive test that requires sedation and is thus unsuitable as a method for wide BE screening. In a significant step forward, the team has developed an easy, five minute outpatient test that is more than 90 percent sensitive for detecting individuals with BE. Patients simply swallow a vitamin pill sized balloon that swabs the esophagus, and that, after retrieval through the mouth, is tested for DNA abnormalities that the investigators discovered are diagnostic of BE. A study describing the development of the test and the results from its clinical trial in patients has been published in today’s issue of Science Translational Medicine.



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.